ERBB2 and invasive breast carcinoma: Cell surface proteins are also attractive drug and immunological targets due to their accessibility such as the transmembrane oncoprotein HER2 (encoded by ERBB2), which is overexpressed in ~20% of invasive breast cancers and can be specifically targeted with the humanised IgG1 antibody, Trastuzumab (Herceptin®)5.